Section 10 · Monograph

Pramipexole (RLS dosing)

Reviewed Nov 2026FDA label

MirapexDopamine agonist

Indications

Moderate-to-severe primary Restless Legs Syndrome (RLS) in adults (FDA-approved indication, distinct from the Parkinson's disease indication covered in the separate general pramipexole/Parkinson's monograph). This entry addresses RLS-specific dosing and safety issues only.FDA-labeled

Periodic limb movement disorder (PLMD) — off-label, related dopaminergic mechanism.Off-label

Pramipexole is a non-ergot dopamine agonist with high specificity and full intrinsic activity at the D2-subfamily of dopamine receptors, with particular affinity for the D3 receptor subtype.
The precise mechanism of benefit in RLS is not fully established, but is believed to involve correction of dysfunction in the diencephalic-spinal dopaminergic pathway implicated in RLS pathophysiology (distinct from the nigrostriatal degeneration targeted in Parkinson's disease).

RLS dosing uses the low-strength tablets only (0.125 mg, 0.25 mg, 0.5 mg) — distinct from the higher Parkinson's disease dosing range (up to 4.5 mg/day, TID dosing).
Initial dose: 0.125 mg once daily, taken 2-3 hours before bedtime.
Titration: increase to 0.25 mg once daily, then to 0.5 mg once daily, with a minimum of 4-7 days between dose increases based on efficacy/tolerability.
Maximum FDA-approved RLS dose: 0.5 mg once daily (RLS is dosed once daily at bedtime, unlike the multiple-daily-dose regimen used in Parkinson's disease).
Before initiating any dopaminergic agent for RLS, check serum ferritin/iron studies — iron deficiency (ferritin <75 mcg/L per common expert consensus) should be corrected first, as it can both cause/worsen RLS and increase augmentation risk.

Renal impairment: pramipexole clearance is significantly reduced in renal impairment; use caution, individualize dosing, and extend intervals between dose increases in patients with reduced renal function.

No contraindications are listed in FDA labeling other than known hypersensitivity to pramipexole or any formulation component.

Cimetidine — increases pramipexole AUC by ~50% and half-life by ~40%; dose adjustment may be needed.
Other inhibitors of the renal organic cation transport system (diltiazem, ranitidine, quinidine, quinine, verapamil) — decrease pramipexole clearance by roughly 20%.
Dopamine antagonists (antipsychotics, metoclopramide) — may diminish pramipexole's effectiveness; generally avoid.
CNS depressants/alcohol — additive sedation and risk of sudden sleep episodes.
Other dopaminergic agents — additive dopaminergic adverse effects.

Common (RLS trials): nausea (16% vs. 5% placebo, dose-related), headache, somnolence (6% vs. 3%), fatigue, constipation, dry mouth.
Sudden sleep onset: patients have reported falling asleep without warning during activities of daily living, including driving.
Orthostatic hypotension, especially during dose titration.
Impulse control disorders: intense urges to gamble, hypersexuality, compulsive shopping, and binge eating; ask directly at follow-up.
Hallucinations (uncommon in the RLS population specifically — 1 of 889 RLS trial subjects — but well described in Parkinson's populations).
AUGMENTATION (RLS-specific, clinically critical): paradoxical worsening of RLS with chronic dopaminergic therapy — earlier onset of symptoms, increased symptom intensity, shorter latency to symptom onset with rest, and spread of symptoms to previously unaffected body parts. Occurred in 12% of pramipexole-treated patients vs. 9% on placebo in the pivotal long-term trial. Risk increases with treatment duration and higher doses. Management: do NOT simply increase the dose; consider moving the dose earlier in the day, checking/repleting iron stores, or switching to a non-dopaminergic agent (e.g., gabapentin enacarbil) with gradual dopamine agonist taper.
Withdrawal: abrupt discontinuation can cause symptom worsening beyond baseline; a taper is recommended when discontinuing after chronic use.

At every follow-up visit, specifically screen for augmentation: earlier symptom onset, increasing severity, spread to new body regions, reduced duration of dosing benefit.
Baseline and periodic serum ferritin/iron studies.
Screen for impulse control disorders via direct questioning at each visit.
Assess for excessive daytime somnolence/sudden sleep episodes; counsel about driving risk.
Orthostatic blood pressure, particularly during titration.
Periodic skin examination (dopamine agonist class-level melanoma monitoring recommendation).
Renal function, given dose-dependent clearance changes.

Pregnancy: Limited human safety data. RLS in pregnancy is generally managed first with iron repletion and non-pharmacologic measures; dopamine agonists are typically avoided in pregnancy given limited safety data.
Lactation: Pramipexole inhibits prolactin secretion and may suppress lactation; not known whether it is excreted in human milk.